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Introduction
Today, preventive chemotherapy (PC) is the main strategy to 
control the morbidity that is caused by soil-transmitted 
helminths (STHs), which include (Ascaris lumbricoides, Trichuris 
trichiura, Necator americanus and Ancylostoma duodenale). 
For this, a single, oral dose of albendazole (ALB; 400 mg) or 
mebendazole (MEB; 500 mg) is periodically administered to 
at-risk populations (i.e., preschool-aged (preSAC), school-aged 
children (SAC) and women of reproductive age)1. The 
treatment coverage of SAC in control programs has increased 
from approximately 30% in 2010 to 69% in 20172. The ultimate 
goal is to reach a 75% coverage in target populations and to 
push towards an elimination of the public health problems 
associated with moderate-to-heavy intensity STH infections3. 
As of 2017, 21 countries have received PC STH coverage 
≥75% for 5 years or longer and seven countries have eliminated 
STH as a public health problem4.
The ever-increasing amount of anthelmintic treatments provided 
to the population could eventually give rise to the development 
of anthelmintic resistance (AR), as it has occurred in veterinary 
medicine5–7, where AR was detected in helminth populations 
within a decade following the introduction of any anthelmintic 
class8. First, the two drugs provided in STH control programs 
(ALB and MEB) are both from the same drug class (benzimi-
dazoles; BZs) and have an identical mode of action (preventing 
the polymerization of microtubules). Thus, if AR would arise 
against one of these drugs, it would likely also affect the efficacy 
of the other BZ drug. Second, it is important to note that BZ 
drugs are administered in single doses, a practice that never 
achieves 100% efficacy9–12. Although operationally justified, these 
single-dose drug regimens may further support the development 
of AR. Finally, there are very few alternative drugs that are 
licensed for the treatment of STH infections in humans13,14.
There is thus an urgent need to design a global surveillance 
system that is able to detect diminishing drug efficacy due to 
the development of AR in STHs. In parallel, drugs of different 
anthelmintic classes and modes of action should become 
more accessible, and the discovery and development of novel 
treatments stimulated.
Currently, there is no global surveillance system to monitor 
the efficacy of anthelmintic drugs or the emergence of AR. As a 
result, we have an inadequate understanding of the current 
efficacy of the administered drugs. There are some important 
obstacles to address that complicate the implementation of 
such a global surveillance system. First, there are only a limited 
number of laboratories and staff with sufficient experience 
to perform drug efficacy surveys and to analyse and report the 
data. Second, there is no quality assurance system in place to 
guarantee the accuracy of the obtained data. Third, at this time, 
there are no validated markers linked to AR in human STHs or 
diagnostic methods that allow for an early, on-site detection 
of AR. Finally, there is an overall lack of guidance on how to 
design surveys to monitor drug efficacy within PC programs.
In 2016, the Bill and Melinda Gates Foundation funded 
the Starworms project (Stop Anthelmintic Resistant Worms; 
www.starworms.org)15. The main objective of this project is to 
strengthen the monitoring and surveillance of drug efficacy and 
AR in STH control programs. In a first work package of the 
Starworms project, we evaluated different diagnostic methods 
to measure drug efficacy and further investigated the presence 
and distribution of AR-related single nucleotide polymorphisms 
in STHs16,17. The current protocol describes the objectives and 
approach for the second work package of the Starworms project, 
and briefly discusses the expected output.
The overall aim of the studies performed as part of the second 
Starworms work package is to pilot a surveillance system to 
assess anthelmintic drug efficacy and the emergence of AR in 
eight countries were PC coverage has been high for at least five 
years.
The specific objectives are to:
1.     Assess the prevalence of moderate-to-heavy intensity 
infections of the different STHs.
2.     Assess the drug efficacy of a single dose of BZ drugs 
against STH infections.
3.     Assess the frequency of the ß-tubulin single nucleotide 
polymorphisms (SNPs) linked to BZ resistance.
4.     Identify implementation-related barriers and opportunities 
for monitoring drug efficacy and AR in national STH 
control programs.
5.     Expand the Starworms repository of STH samples.
Protocol
Field trial design
A drug efficacy trial will be performed in eight STH-endemic 
countries during their national PC program. These trials were 
registered on the 22nd of November 2019 on Clinicaltrials.gov 
(ID: NCT04177654; https://clinicaltrials.gov/ct2/show/
NCT04177654). The study will focus on the target population of 
the country’s STH control programs, namely SAC (age 5–14). 
At the start of the trial (baseline), SAC will be required to 
provide a fresh stool sample. Children that meet all inclusion 
criteria and none of the exclusion criteria (Table 1) will be 
enrolled in the study and will receive a study-specific identi-
fier. Under direct supervision, each participant will be treated 
with a single oral dose of BZ drug. The choice of BZ drug will 
depend on the drug used in the STH control program (Table 2). 
The drug used in the study will be provided by the national PC 
program. The duplicate Kato-Katz thick smear method will 
be used to determine the fecal egg counts (FECs; expressed 
in eggs per gram of stool (EPG)) for each STH in the stool 
samples provided by the children. Two to three weeks post drug 
administration, a second stool sample will be collected from 
each child that tested positive for any STH during baseline 
screening. These stool samples will again be examined by 
duplicate Kato-Katz. Children who remained positive for any 
STH following treatment will receive a second treatment with 
a BZ drug. Baseline samples that are positive for any STH as 
well as all follow-up samples will be preserved for molecular 
analysis (see below). The different steps of the trials are shown in 
Figure 1.
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Table 1. Inclusion and exclusion criteria endorsed during the recruitment of participants for the field trials.



































WHO Region / 
Country
Median national 
coverage* of SAC 
(%) 
Year from 
when ≥ 50% 
PC coverage 





rounds of PC 
with BZ/year 
Other NTD programs 
(drug(s) used)
        Africa
   Ghana 59.0 2009 ALB 1 – 2 Schistosomiasis 
(PZQ) LF (IVM + ALB)
   Rwanda  98.6 2008 ALB 1 – 2  Schistosomiasis 
(PZQ)
   Senegal 60.0 2012 ALB 1 Schistosomiasis 
(PZQ) LF (IVM + ALB)
        The Americas$#
   Nicaragua 100 2013 MEB 1 _
        South-East Asia
   Bangladesh 86.4 2012 MEB/ALB 2 LF (DEC + ALB)
        Western Pacific
   Cambodia  95.1 2003 MEB 2 _
   Lao PDR  86.9 2006 MEB/ALB 1 – 2  LF (DEC + ALB)








Study sites were selected in two consecutive steps. First, 
countries were selected, after which potential study sites within 
each country were identified. The selection of the countries 
was based on the Preventive Chemotherapy and Transmission 
Control (PCT) databank for soil-transmitted helminthiasis, 
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Figure 1. An overview of the different consecutive steps of the 
drug efficacy trials.
accessed in Nov 2017. This databank documents the number 
of preSAC and SAC requiring PC and the coverage for these 
at-risk populations for each country. We selected countries that:
•     are part of WHO African Region (AFRO), Region of the 
Americas (AMR), South-East Asia Region (SEAR) or 
Western Pacific Region (WPR).
•     reported national PC coverage data for the last 5 years 
(from 2012 to 2016)
•     had a median national PC coverage for SAC of at least 
50%
•     reported subnational coverage data to WHO HQ for the 
last 4 years (from 2013 to 2017)
The cut-off for the median national PC coverage was set 
arbitrarily at 50%. This cut-off allows the inclusion of countries 
(i) where PC coverage was increasing over time and (ii) where 
PC coverage was high in some areas, but low in other areas. The 
selection on the availability of subnational data was made at 
WHO headquarters (by AMi). From the 138 countries included 
in the PCT data bank for STH, 13 countries met the aforemen-
tioned criteria. In collaboration with WHO regional offices, a 
subset of eight countries were selected from these 13 countries. 
For each of these countries, the median coverage of SAC 
between 2012 and 2016, the BZ drugs administered, the 
number of rounds of PC of BZ drugs and the presence of 
other neglected tropical disease (NTD) programs (schistosomiasis 
and lymphatic filariasis) is reported in Table 2.
Within these selected countries, we further identified geo-
graphical areas to which decisions on implementation of MDA 
apply (implementation units; IUs). We selected those IUs where: 
(i) subnational coverage data on SAC was reported between 
2013 and 2016 and (ii) the minimum cumulative coverage of 
SAC over this period was at least 90%. The cumulative coverage 
equals to the sum of coverage of each round of PC. Coverage 
was calculated by dividing the number of SAC covered in a 
particular round of PC over the total number of SAC in that IU.
In the case that more than 10 IUs met the aforementioned 
criteria, and that there were no obvious differences that 
allowed to further prioritize IUs (e.g. total number of rounds 
over the 4-year period and presence of schistosomiasis/ 
lymphatic filariasis program), the units where ordered accord-
ing to decreasing coverage and the top 10 IUs were selected. 
Table 3 reports per country, the total number of IUs for which 
sub-national data was available, the administrative level at 
which the PC is administered and the number of units withheld 
based on the selection criteria. A list of the IUs is provided 
in Extended data: S1. The final selection of the IU where the 
Table 3. The number of implementation units available 






WHO Region / 
Country
Administrative 






     Ghana District 63 3
     Rwandaa District 31 10
     Senegal Department 67 10
The Americas
     Nicaraguab Department 19 10
South-East Asia
     Bangladeshc District 64 10
Western Pacific
     Cambodiab Province 13 10
     Lao PDR Province 18 10
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study will be performed is done in close collaboration with 
country representatives and will depend on elements such as 
the availability of recent coverage and STH prevalence data, the 
presence of sentinel schools and other practical considerations 
(e.g. laboratory facilities, accessibility of the schools, etc.).
Sample size calculation
A sample size was calculated that allows for correctly identi-
fying IUs where the efficacy of BZ drugs (ALB / MEB) against 
STHs is ‘reduced’, ‘doubtful’ and ‘satisfactory’ with a probability 
of at least 95%. The WHO criteria to classify BZ drugs into 
‘reduced’, ‘doubtful’ and ‘satisfactory’ are summarized in Table 4. 
Given the differences in criteria across both the STH species 
and BZ drugs, a separate sample size was calculated for each 
STH species and for each BZ drug. To calculate the sample 
sizes, a simulation study was performed. This simulation study 
considered variation (i) in egg reduction rates (ERR) across 
STH species and participants, (ii) in baseline FECs across and 
within STH species, and (iii) variation in FECs introduced by 
the egg counting process. Based on the simulation, at least 
150, 140 and 95 complete cases (i.e., participants positive at 
baseline and for which a follow-up sample was also collected 
and screened) are required for Trichuris, hookworm and 
Ascaris, respectively. If a child is positive for more than one 
STH species at baseline it thus serves as a case for each of the 
respective STH species. Extended data: S2 provides a more 
detailed description of the sample size calculation.
Given that the prevalence of STHs can vary significantly across 
schools within one IU, a number of schools per IU will be 
sampled. This number of schools corresponds with the number 
of sub-administrative levels within the selected IU. Per school, 
a random sample of a minimum of 100 participants will be 
enrolled.
Laboratory procedures
Egg counting. Following collection, stool samples will be 
homogenized and an aliquot will be used to prepare two Kato-Katz 
thick smears (standard operating procedure (SOP) in 
Extended data: S3). For each stool sample, two Kato-Katz thick 
smears will be prepared. Within 30–60 min after preparation 
of the slides, the presence of STH eggs is evaluated. The 
number of A. lumbricoides, T. trichiura and hookworm eggs 
counted per slide will be recorded. The two slides from the 
same sample will be examined by two different technicians.
A senior researcher, who is blinded to the initial FECs, will 
randomly selected a subset of samples (10% of total number 
of samples) to re-evaluate. In case of discrepancies, a third 
researcher will recount the STH eggs. Discrepancies will be 
defined as (i) false negatives/positives, (ii) difference in egg 
counts >10 when the total number of eggs counted ≤100 or 
(iii) difference in egg counts >20% when more than 100 eggs 
are counted19. Extended data: S4 provides the SOP regarding the 
quality control of the egg counting.
BZ resistance-associated molecular markers. After performing 
the duplicate Kato-Katz, stool samples aliquots will be pre-
served and stored for future molecular analysis. For each 
sample, a minimum of 2 g of stool will be preserved in an 
equal volume of 100% ethanol. At baseline, samples will be 
preserved if they are positive for at least one STH species. 
During follow-up, every sample will be preserved, irrespective 
of the STH egg counts. Extended data: S5 provides the SOP 
on stool sample preservation. The preserved stool samples will 
be stored at room temperature in sample boxes. Material will 
be shipped to Belgium for DNA extraction and molecular 
analysis. First, a mechanical lysis step including bead beating 
is used to break open the STH eggs and free the parasite 
DNA. After this, the automated QiaSymphony platform will 
purify the DNA from the lysate to maximize the yield of 
STH DNA obtained from the stool sample20. The mechanical 
lysis step will be performed at Ghent University (Belgium) and 
the DNA purification at the Elizabeth-Tweesteden Hospital 
(The Netherlands) (SOP in Extended data: S6). Presence and 
quantity of STH DNA will be assessed Elizabeth-Tweesteden 
hospital by means of qPCR as described previously16,20
We will also assess the presence of genetic markers associated 
with BZ resistance using a variety of molecular tools. A Loop- 
mediated isothermal amplification (LAMP) assay and pyrose-
quencing will be performed at McGill University, Canada21,22. 
A deep amplicon sequencing approach will be tested by 
project collaborators at Calgary University (Canada)23 and a 
novel digital droplet PCR for the detection of β-tubulin gene 
SNPs developed at Ghent University will also be applied.
Selected stool and DNA samples will be stored at Ghent 
University (WHO Collaborating Centre on Monitoring Drug 
Efficacy against soil-transmitted helminthiasis), and will be 
included in the Virtual STH Sample Inventory (VSSI) of the 
Starworms project. This sample repository will form a basis for 
validating novel molecular tools and identifying AR resistance 
mechanisms/markers other than the SNPs in genes encoding 
for the β-tubulins. They will also serve as historic reference 
samples for these IUs.
Identifying implementation-related barriers and 
opportunities to monitor drug efficacy and AR in national 
control programs
By embedding eight drug efficacy studies within the national 
control programs worldwide, we will gain insights into potential 
Table 4. Criteria to classify benzimidazole drug efficacy against 
soil-transmitted helminths18. ERR: egg reduction rates.
Drug Reduced Doubtful Satisfactory
Single, oral dose of 400 mg albendazole
Ascaris ERR ≤ 85% 85% < ERR < 95% ERR ≥ 95%
Trichuris ERR ≤ 40% 40% < ERR < 50% ERR ≥ 50%
Hookworms ERR ≤ 80% 80% < ERR < 90% ERR ≥ 90%
Single, oral dose of 500 mg mebendazole
Ascaris ERR ≤ 85% 85% < ERR < 95% ERR ≥ 95%
Trichuris ERR ≤ 40% 40% < ERR < 50% ERR ≥ 50%
Hookworms ERR ≤ 60% 60% < ERR < 70% ERR ≥ 70%
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barriers and opportunities that are related to the implementation 
of drug efficacy monitoring in national control programs. 
To do so we will (i) estimate the costs (both financial and in 
terms of human resources) to incorporate the monitoring of 
drug efficacy and AR in the national program for each of the 
selected countries (Extended data: S7), (ii) organize focal 
group discussions with key persons in the national program 
associated to identify opportunities and barriers, (iii) field-test 
and evaluate the ParaDrug tool for the automated analysis of drug 
efficacy trials.
Data management
The data that will be collected during the studies will be 
recorded in study-specific record forms (Extended data: S8). 
The original data that is captured in the field will be stored on 
these paper documents. Later, these documents will be scanned 
and stored digitally. The raw data will be entered independently 
by two data entry clerks into study-specific Excel files (Extended 
data: S9; double data entry). Following the double data entry, 
the files of both data entry clerks are evaluated for possible 
discrepancies (SOP in Extended data: S10). If mismatches are 
identified, true values will be verified by checking the original 
record form or its digital copy.
Study coordination and management
Institutional review board (IRB) approval for these studies will 
be obtained from Ghent University and from each individual 
site. The local principal investigator (PI) is responsible to 
perform the trial procedures according to the original study 
protocol and using provided SOPs. The local project PI and 
the Starworms team at Ghent University will work together to 
coordinate the study. A member of the Starworms team will 
visit the study site prior to the start of the efficacy trial to inform 
local team members on the study design, to familiarise them 
with the different study documents and to provide both theoreti-
cal and practical training on the different laboratory techniques 
that will be used during the trial.
Statistical data analysis
Following duplicated data entry and quality control, the data will 
be stored in a final, protected dataset to be used for statistical 
analysis. At the end of the project, and after finishing and 
publishing the data, this dataset will be published on the project 
website (www.starworms.org). All statistical analysis will be 
performed in R24. Levels of significance will be set at p <0.05.
Assessing infection prevalence and intensities. Samples 
collected at baseline that contain helminth eggs will be classi-
fied into low, moderate, or heavy intensity infection based on 
the thresholds proposed by WHO25. The proportion of moder-
ate-to-heavy infection intensities will be determined separately 
for each STH species and study site.
Assessment of the drug efficacy. The efficacy of a single, oral 
dose of BZ drug will be calculated and reported separately for 
each of the STHs (Ascaris, Trichuris and hookworms), using the 
following formula:
ERR 100% (arithmetic mean (FEC at baseline) - arithmetic mean (FEC at follow-up))
arithmetic mean (FEC at baseline)
= ×
The corresponding 95% confidence intervals (95% CI) will 
be calculated as described by Levecke et al., 201826. The drug 
efficacy classification will be based on the WHO criteria 
(Table 4).
Ethical approval and consent to participate
The IRB of the Faculty of Medicine of Ghent University 
(Belgium) has reviewed and approved the study protocol 
(Ref. No B670201837218). The institutional review boards 
associated with each trial site will also review the study 
protocol. At the start of each trial, the local PI and a team of 
field officers will visit the schools that will be included in the 
study. School directors, teachers, children and if possible, the 
parents will be informed on the planned trial and sampling 
methods. The written consent form will be prepared in the 
local language and provided to the children’s parents or 
guardians. Only children (i) who are willing to participate and 
(ii) whose parents or guardians have signed the informed consent 
form will be included in the study. For children older than 
12, an additional, separate written informed consent form will 
be provided. The used consent forms are provided as part of a 
summarized protocol in English, French and Spanish (Extended 
data: S11–13). Material transfer agreements between the 
leading local organization and Ghent University will govern the 
transfer of collected samples.
Dissemination of study results
The study results obtained from the different drug efficacy 
trials will be combined and published in peer-reviewed scien-
tific journals. Drug efficacy reports will be prepared per country 
and shared with key stake holders including country program 
managers and WHO representatives at the local and interna-
tional level. Study data will be published as supplementary 





To our knowledge, this is the first time a large-scale, multicentre 
study will document global patterns of anthelmintic drug efficacy 
and the emergence of AR applying standardized methodologies. 
We applied a rigorous selection approach performed in close 
collaboration with WHO headquarters, the different representa-
tives from each WHO region and national program managers. 
This not only allowed for a transparent and strategic identifi-
cation of countries and areas with an elevated risk to develop 
AR, it also envisioned that this approach is essential to 
strengthen the capacity within the national programs to independ-
ently continue monitoring of drug efficacy and the emergence 
of AR.
It is expected that the results will provide important information 
on (i) the current STH prevalence and infection intensity after 
multiple rounds of intense PC; (ii) global patters of efficacy 
of BZ drug administered in the control program; and (iii) the 
presence of genetic markers associated with BZ resistance. 
Besides the research findings, this study will also form 
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an important resource for countries that want to establish 
their own surveillance system and for future research on the 
molecular detection of AR. For example, on top of the general 
selection framework, the different SOPs, it also includes a 
brief summary of the protocol and informed consent forms, 
that can be further customized to national requirements prior 
submission for ethical approval. To enhance the use of these 
documents, the documents are made available in English, 
French and Spanish (Extended data: S11–13). Finally, the 
collected and stored stool samples will allow validation of future 
molecular technologies for the detection of AR or to identify 
novel potential molecular markers associated with AR in STH.
Data availability
Underlying data
No data are associated with this article.
Extended data
Open Science Framework: StarwormsWP02, https://doi.
org/10.17605/OSF.IO/M6VN727.
This project contains the following extended data:
•     S1: Program information on potential implementation 
units between 2013 and 2017 for each of the selected 
countries.
•     S2: Detailed sample size calculation.
•     S3: An SOP on how to perform the Kato-Katz thick 
smear method.
•     S4: An SOP on quality control of stool-based microscopic 
methods.
•     S5: An SOP on sample preservation.
•     S6: An SOP on DNA extraction from preserved stool 
samples.
•     S7: Excel template used to estimate cost of trials in 
English, French and Spanish.
•     S8: Record forms used for the trials.
•     S9: Excel file for data entry.
•     S10: An SOP on screening data files of two data entry 
clerks for mismatches and errors.
•     S11: Summarized protocol and informed consent forms 
in English.
•     S12: Summarized protocol and informed consent forms 
in French.
•     S13: Summarized protocol and informed consent forms 
in Spanish.
Data are available under the terms of the Creative Commons 
Zero “No rights reserved” data waiver (CC0 1.0 Public domain 
dedication).
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